Anti-Payload Antibodies

Antibody-drug conjugates are measured as a set of related species rather than as a single molecule, and the payload is the component that makes them difficult. It is a hapten of 500–1,500 Da, present in circulation both attached to the antibody and free, at concentrations that differ by orders of magnitude between the two states. Anti-payload antibodies are the critical reagents that make the conjugated species accessible to ligand binding assays and that provide the capture step in hybrid immunoaffinity LC-MS methods.

Creative Diagnostics supplies monoclonal anti-payload antibodies, matched hapten conjugates and finished quantitative kits across the principal payload mechanism classes.

Browse by mechanism class:

What ADC Bioanalysis Requires of a Payload Antibody

The conjugate is a heterogeneous, time-varying mixture. An ADC preparation is not a single chemical entity. Conjugation produces a distribution of drug-to-antibody ratios (DARs), and the average DAR reported for a product represents the mean of that distribution. Site-specific conjugation generally produces a narrower and more defined DAR distribution, whereas stochastic conjugation to lysine residues or reduced interchain cysteines can generate greater heterogeneity. Many early auristatin-based ADCs were developed around an average DAR of approximately four, while some newer topoisomerase I inhibitor ADCs have been engineered at substantially higher DARs. More importantly for bioanalysis, this distribution can change after administration. ADC species with higher drug loading can exhibit faster clearance, while payload loss through linker cleavage, hydrolysis, reduction, or other deconjugation processes can progressively alter the DAR distribution in circulation. This is why ADC pharmacokinetic characterization typically requires more than a measurement of total antibody. Commonly evaluated analytes include total antibody, conjugated antibody or ADC, conjugated payload, unconjugated payload, and, where relevant, payload- or linker-derived metabolites. Together, these measurements provide a more complete picture of ADC exposure, deconjugation, and payload disposition.

This is where an anti-payload antibody can add value: when appropriately characterized, it can enable selective detection or affinity capture of payload-bearing species in ligand-binding and hybrid immunoaffinity LC-MS workflows.

Figure 1. Analyte coverage of circulating ADC species.

• Linker Chemistry Shapes the Analyte Profile

The linker is not simply a structural connection between the antibody and payload. Its chemistry influences how the ADC behaves in circulation, how the payload is released or retained after cellular processing, and which molecular species become relevant for bioanalysis.

• Payload Antibody Selection Should Follow the Intended Analyte

Free payload and conjugated payload are not necessarily equivalent assay targets. A clone raised against the free payload may show different recognition of a linker-bound or ADC-associated form because the linker and antibody scaffold can alter epitope accessibility. For this reason, payload antibody selection should consider:

1. Target analyte: free payload, conjugated payload, or payload-containing catabolite
2. Epitope accessibility: whether conjugation alters antibody recognition
3. Linker and conjugation chemistry: whether they affect the molecular species being measured
4. Selectivity: discrimination from related payloads, metabolites, and analogues
5. Assay compatibility: suitability for ligand-binding or immunoaffinity LC-MS workflows

Analytical Methods for ADC Payload Measurement

Three method classes are in routine use, and they are not substitutes for one another. The choice is driven by which analyte is being reported.

Figure 2. The anti-payload antibody performs the capture step in both ligand binding and hybrid immunoaffinity workflows

Matrix and Sample Handling Considerations for Payload Bioanalysis

ADC study samples contain the therapeutic antibody at concentrations far above those of the payload, together with endogenous immunoglobulin. Several consequences follow for a payload assay:

1. Free payload assays should tolerate a large excess of conjugated payload, which is chemically identical to the analyte and available for antibody binding once the sample is disturbed.
2. Sample handling can shift the equilibrium. Linker hydrolysis or thiol exchange during storage or processing changes the free-to-conjugated ratio, so stability under the intended handling conditions should be consider as part of method validation.
3. Anti-drug antibodies (ADAs) may interfere with bioanalytical assays. ADAs can affect the capture or detection of ADC-related species and may require assessment of assay tolerance or appropriate mitigation strategies during method development.
4. Matrix evaluation is essential. Performance in assay buffer may not predict performance in plasma or serum. Payload antibody selectivity and assay performance should therefore be evaluated in the intended biological matrix, including relevant matrix variability.

Product Lines

• Topoisomerase I Inhibitors

Camptothecin-derived payloads account for a growing share of the ADC pipeline. Deruxtecan (DXd) is released from a cleavable glycine-glycine-phenylalanine-glycine tetrapeptide linker and is membrane-permeable, which produces measurable extracellular payload and underlies the bystander effect associated with this class. SN-38 is the active metabolite of irinotecan. Both are structurally related to exatecan, so a well-designed clone can span more than one member of the family — an advantage in a class where several payload variants are in development simultaneously.

DXd (Deruxtecan)

SN-38

• Microtubule Inhibitors

Auristatins and maytansinoids remain among the most widely used ADC payload classes. Closely related payloads such as MMAE/MMAF and DM1/DM4 can require specific discrimination in bioanalytical assays. Broad payload recognition alone may not be sufficient when the intended analyte must be distinguished from related payloads, metabolites, or analogues. MMAF contains a charged C-terminal phenylalanine that reduces membrane permeability relative to MMAE and has been used with both cleavable and non-cleavable linker strategies. The resulting analyte profile depends on the payload, linker, conjugation chemistry, and intracellular processing. Payload antibody selection should therefore be based on the specific ADC construct and intended analyte, rather than the payload family alone.

Auristatins (MMAE / MMAF)

Clone 3F3 has been used by an independent group as the capture antibody in a plate-based ELISA quantifying free MMAE in mouse serum, run alongside a validated LC-MS/MS method in a pharmacokinetic study (Mak SY et al., Sci Rep, 2024; PMID 38744902). Plates were coated at 3 µg/mL.

Maytansinoids (DM1 / DM4)

Maytansinoids bind tubulin at or near the vinca site. DM1 and DM4 are thiol-bearing derivatives of maytansine that differ in the length and steric hindrance of the thiol-containing side chain. DM1 is commonly paired with a non-cleavable thioether linker, in which case the principal circulating catabolite retains a lysine residue and part of the linker rather than appearing as free DM1; DM4 is commonly paired with a reducible disulfide, and its catabolites may be S-methylated. Neither pairing is fixed, and both payloads appear with other linker chemistries. So an assay intended to measure released drug should be designed around the catabolite the specific construct actually generates. Because the two payloads differ only in that side chain, clone selection turns on whether the method needs to resolve them. Both single-target and dual-recognition clones are available.

Clone G2E6 has been used by an independent group as the capture antibody, at 1 µg/mL, in a sandwich ELISA measuring tissue uptake of an intact DM4 conjugate, with an anti-human IgG-HRP secondary for detection.

• DNA Damaging Agents

Duocarmycins, pyrrolobenzodiazepine (PBD) dimers, calicheamicin, and anthracyclines comprise a structurally diverse group of DNA-damaging payloads. Their high potency and diverse chemistries can create distinct bioanalytical requirements; PBD dimers, for example, can exhibit low-picomolar cytotoxicity, which pushes the required sensitivity for free drug measurement correspondingly lower. And conjugation strategy differs, Calicheamicin ADCs have commonly used acid-labile hydrazone and disulfide-containing designs, whereas PBD and duocarmycin ADCs have commonly employed cysteine-conjugated, protease-cleavable peptide linkers such as valine-alanine or valine-citrulline. The released species therefore differs by construct, and an assay should be designed around the one actually generated.

• RNA Polymerase Inhibitors

α-Amanitin inhibits RNA polymerase II and can exert cytotoxicity in both dividing and non-dividing cells, making it an attractive payload for tumors with slowly proliferating or quiescent cell populations. As a bicyclic octapeptide, its structure offers only a limited number of suitable sites for chemical modification, because many positions are poorly suited for conjugation or important for RNA polymerase II binding. The 6'-hydroxyl group of tryptophan is a commonly used attachment site, with the aspartate carboxyl group and dihydroxyisoleucine hydroxyl providing alternative conjugation sites. These structural constraints are relevant not only to ADC linker design but also to the design of amanitin-based immunogens, where the choice of conjugation site and spacer can influence epitope presentation and antibody recognition.

• Chemotherapy Drugs

Conventional cytotoxic agents including methotrexate continue to appear as ADC payloads. Because these compounds may also be administered systemically as standalone drugs, the assay context should be defined explicitly. The same drug measured as a released ADC payload versus a systemically administered therapeutic can present different concentration ranges, matrix contexts, and potential interferences.

Custom Development

Where a payload is not covered by catalog clones, such as a novel linker-payload construct, a proprietary warhead, or an emerging class such as immune-agonist payloads.

Anti-Hapten Antibody Production Custom Monoclonal Antibody Against Small Molecules

For programmes requiring validated methods and sample analysis rather than reagents, Creative Diagnostics also runs PK Assays for Antibody-Drug Conjugates (ADCs) and Anti-Drug Antibodies Assay services.

FAQ